MRKR Marker Therapeutics

Marker Therapeutics (NASDAQ:MRKR) Shares Down 2.6%

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Rating)'s stock price fell 2.6% on Tuesday . The company traded as low as $0.28 and last traded at $0.29. 134,907 shares traded hands during mid-day tradi

12-07 17:52

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersCosmos Holdings (NASDAQ:COSM) shares moved upwards by 32.2% to $0.43 during Wednesday's pre-market session. The market value of their outstanding shares is at $36.2 million. NeuroBo Pharmaceuti

11-23 21:11

Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely

11-23 18:33

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersOncoSec Medical (NASDAQ:ONCS) shares rose 31.9% to $6.4 during Tuesday's pre-market session. The market value of their outstanding shares is at $11.4 million. TransCode Therapeutics (NASDAQ:RNA

11-22 21:11

Top Premarket Gainers

07:55 AM EST, 11/22/2022 (MT Newswires) -- ObsEva (OBSV) shares rallied 53% on a planned sale of Ebopiprant license to XOMA for up to $113 million. OncoSec Medical (ONCS) shares surged 31%, extending

11-22 20:57

Marker Therapeutics Announces FDA Clearance Of IND For MT-601

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological mal

11-22 20:11

Marker Therapeutics Announces FDA Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

HOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunoth

11-22 20:06

MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates

11-11 23:18

Marker Therapeutics Q3 EPS $(0.08) Up From $(0.15) YoY

Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year.

11-11 05:45

Earnings Flash (MRKR) MARKER THERAPEUTICS Posts Q3 Revenue $3.95M

04:17 PM EST, 11/10/2022 (MT Newswires) --

11-11 05:26